PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2073725
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2073725
Laboratory Animal Medicine Market size was valued at US$ 7,105.9 Million in 2025, expanding at a CAGR of 5.8% from 2026 to 2033.
The Laboratory Animal Medicine (LAM) market encompasses pharmaceuticals, vaccines, anesthetics, analgesics, nutritional supplements, and healthcare products specifically developed for laboratory animals used in biomedical research, drug discovery, toxicology studies, and academic research. Market growth is driven by rising investments in pharmaceutical and biotechnology R&D, increasing preclinical testing activities, and the expanding use of animal models in translational research. Key industry trends include the adoption of advanced veterinary care practices, precision medicine approaches, and digital animal monitoring technologies aimed at improving animal welfare and research outcomes. However, stringent regulatory requirements, high compliance costs, and ethical concerns regarding animal testing remain significant challenges. Despite these constraints, the expansion of contract research organizations (CROs), specialized research facilities, and translational medicine programs continues to create substantial growth opportunities for the market.
Laboratory Animal Medicine Market- Market Dynamics
Rising Investments in Biomedical and Preclinical Research
One of the major reasons for growth in the laboratory animal medicine market is the increased amount of money being spent on biomedical research and developing new drugs. Before testing new drugs in clinical trials, assessment of their safety, effectiveness, and potential toxicity must be completed using non-human species, termed "model organisms". Models will continue to play an important role in developing new therapies, particularly cancer, cardiovascular, neurological, and infectious disease treatments, according to the National Institutes of Health (NIH). NIH-funded studies greatly depend on laboratory animals for research into how diseases are processed and how to develop new treatments for diseases.
In addition, AAALAC International has also reported that 1,140-plus laboratory animal care organizations across 52 countries or regions have been accredited, suggesting that laboratory animal research has a continuous and growing support structure throughout the world. Increasing numbers of accredited research facilities and increasing pharmaceutical/biotechnology R&D expenditures have driven demand for veterinary care services (i.e., diagnostics, disease surveillance, anesthetics, vaccines, welfare management solutions) developed specifically for laboratory animals.
The Global Laboratory Animal Medicine Market is segmented by Product, Animal Model, Application, End User, and Region.
The Laboratory Animal Medicine Market was majority led by the therapeutics and preventive medicines segment, as they play a vital role in providing translational research, and supporting drug discovery, vaccine development and preventive healthcare strategies. Use of Laboratory Animals allow researchers to explore disease mechanisms, evaluate safety and effectiveness of therapeutics, and establish preventive methods before human clinical application. They also support early detection of diseases and developing targeted protocols for research; thus, enabling further advancements in biomedical innovation. For example, as identified by an industry source, around 80% of all pre-clinical drug development programmes utilize animals to evaluate pharmacological and toxicological activity before advancing to human clinical trials.
Laboratory Animal Medicine Market- Geographical Insights
Laboratory Animal Medicine Market North America was the most significant contributor to the global laboratory animal medicine market in 2025. The United States has a sophisticated pharmaceutical and academic research system that drives substantial investment for the development of innovations in medical care, contributing to the growth of Laboratory Animal Medicine and solidifying its place as a leader in healthcare innovation internationally. The presence of numerous global pharmaceutical companies and the growing number of specialized contract research organizations such as Charles River Laboratories leads to the increased use of in-vivo models for pharmaceutical research and the corresponding growth of laboratory animal medicine. An example of the significant contribution of laboratory animal medicine and in-vivo models to the growth of the U.S. laboratory animal medicine market occurred in November 2025, when the U.S. Food and Drug Administration approved KOMZIFTI as a treatment for adult patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with a suitable NPM1 mutation who have no alternative treatment options.
United States Laboratory Animal Medicine Market- Country Insights
NIH (National Institutes of Health) recognizes a new project to grow innovative research and human-derived science and de-emphasize animal use, thereby making the United States the global leader in biomedicine. The region has created rigorous ethical practices and accreditation systems (including the founding of AAALAC International to promote the humane treatment of animals used for research through voluntary accreditation) to provide assurance of animal welfare in biomedicine.
The Laboratory Animal Medicine market is a very fast-paced industry shaped by various innovations revolving around veterinary therapeutics, diagnostics, and the care of Laboratory Animals. As a result of these innovations, participants compete based on product quality, regulatory compliance, animal welfare regulation adherence, and the scope of disease prevention as well as monitoring capabilities. Participants within the marketplace further enhance their position via the implementation of strategic initiatives such as investment in R&D, partnerships with research institutions, acquisitions of other participants, and geographical expansion. Furthermore, rising adoption rates of precision diagnostics and digital health monitoring technologies will increase the competitive differentiation among market participants. Other key players that will use their research capabilities and vast networks globally to meet the needs of the Laboratory Animal Medicine market are Thermo Fisher Scientific Company, Merck & Co., Inc., Boehringer Ingelheim, Elanco Animal Health, Zoetis, and QIAGEN.
In February 2026, The QIAsprint Connect automation system developed by Qiagen is a comprehensive solution for preparing DNA and RNA samples in laboratories. This enables the inclusion of lab animals, such as mice, rats, etc., as part of experimental work in the life sciences, particularly in the field of biomedical and preclinical studies.
In November 2025, A leading veterinary pathology lab in the U.K. and Ireland, Zoetis Inc.'s acquisition of Veterinary Pathology Group (VPG) comprises a network of labs across both countries that will help to extend Zoetis' existing programs into new (and more varied) veterinary pathologist services. This acquisition also reaffirms Zoetis commitment to continually enhance animal welfare through the delivery of state-of-the-art diagnostic tools that will improve animal health and well-being.